MORGANTOWN – Viatris is proceeding with the planned closure of a Mylan pharmaceutical plant in San Carlos, Calif., the company told The Dominion Post Friday.
The company responded to a request for information about the closure after The Dominion Post received word it is happening.
Mylan announced the closure in March 2020, Viatris said, before the merger with Upjohn to create Viatris. Mylan sent out WARN Act Notices to employees and government officials about the pending closure that month.
In a statement sent Friday, Viatris said, “In October 2021, we updated the San Carlos WARN Act Notices to government officials, notifying them of current anticipated employment termination dates. As previously communicated, employees are being offered severance packages that include severance pay, benefit continuation, and outplacement counseling and assistance.”
The pharmaceutical news site Fierce Pharma reported that 75 employees will be laid off.
Fierce Pharma said Mylan acquired the plant from Swiss drugmaker Novartis, which manufactured cystic fibrosis drugs there. Mylan bought the drugs in 2018 for $463 million and then took an option on the plant itself the following year.
Tweet David Beard @dbeardtdp Email dbeard@dominionpost.com
